Are the New ACR/EULAR Criteria the Ultimate Answer for Polymyalgia Rheumatica Classification?

DARIO CAMELLINO and MARCO A. CIMMINO

J Rheumatol 2016;43;836-838
http://www.jrheum.org/content/43/5/836

1. Sign up for TOCs and other alerts
http://www.jrheum.org/alerts

2. Information on Subscriptions
http://jrheum.com/faq

3. Information on permissions/orders of reprints
http://jrheum.com/reprints_permissions

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Are the New ACR/EULAR Criteria the Ultimate Answer for Polymyalgia Rheumatica Classification?

Polymyalgia rheumatica (PMR) is a diagnostic limbo. If a patient is evaluated by an experienced clinician who records the usual set of signs and symptoms along with the pertinent increased inflammatory markers, the diagnosis is usually correct. However, in several instances, PMR may evolve or transform into elderly onset rheumatoid arthritis (EORA), a switch that cannot be easily predicted and is usually recognized only during followup. When less experienced clinicians are involved, overdiagnosis and underdiagnosis of PMR are relatively frequent because several conditions may mimic the disease, and a gold standard for diagnosis confirmation is lacking.

The availability of the recent American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria is expected to improve PMR classification. Clinicians may also be enticed to apply these criteria in the individual patient although, as widely stated, criteria should be used for classification only. The multifaceted essence of PMR may account for the wide range of its clinical presentations, making it difficult to identify a 1-size-fits-all set of criteria.

In this issue of The Journal, Ozen, et al describe a multicenter study dealing with the comparison of different sets of PMR classification criteria, including the ACR/EULAR criteria. The main findings of this study, which confirmed the overall good performance of the criteria, are that they are not optimal in differentiating PMR from seronegative polyarthritis and that, if a cutoff for laboratory inflammation is included, performance can increase. By comparing the existing sets of criteria, several studies from the literature obtained different results (Table 1). In Ozen’s study, the new ACR/EULAR criteria showed a moderate-to-good discriminating capacity between PMR and non-PMR. However, the best performance was obtained by the Chuang, et al criteria, also in the case of differentiation between PMR and EORA. In accordance with previous findings, the Bird criteria showed the best sensitivity (94%), while those of Jones and Hazleman and of Chuang, et al, showed the highest specificity. The unexpected finding of Ozen’s study is that the ACR/EULAR criteria showed more sensitivity than specificity, contrary to what was observed in the original article and in Macchioni, et al (Table 1). In addition, specificity of the ACR/EULAR criteria increased when they were used to differentiate PMR from RA (but not from its seronegative subset), again in disagreement with the original study, which showed better performance when the criteria were used to discriminate between PMR and non-inflammatory shoulder diseases. This observation is surprising, because EORA is unanimously considered the most challenging differential diagnosis.

Is PMR the same disease for all clinicians? It is ironic that even if the same ingredients are used, the resulting cocktail is so unpredictable. In fact, there is an overlap of 80% in the different items of the 6 most frequently used criteria. In particular, age over 50 years is considered in 4/6, elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) in 6/6, morning stiffness in 4/6, bilateral shoulder pain and stiffness in 6/6, and exclusion of other conditions, especially peripheral arthritis in 5/6. However, the definition of the single item is somewhat different. The nature of the patients, control group population, and clinicians who apply the criteria may further explain some of the discrepancies. In the ACR/EULAR study, the population studied was a prospective cohort of new patients, whose diagnosis was reevaluated after 6 months; the clinicians, who were from 21 centers in 10 countries, had considerable experience in the disease and met several times to agree on diagnosis standardization; the control group were patients with conditions mimicking PMR, including RA and noninflammatory shoulder conditions. The single-center study by Macchioni, et al was retrospective, patients were consecutively enrolled and followed by expert clinicians, diagnosis was confirmed at 12 months, and controls included mainly early RA and various other rheumatic conditions. Ozen’s study was...
prospective and multicenter (18 centers), enrolled patients showed the same features as the ACR/EULAR study, and diagnosis was validated after 12 months. The rate of misclassification was similar; in the original ACR/EULAR study, 8% of patients moved from the PMR to the control cohort and 4.7% of controls were reclassified as PMR by the end of followup; and in Ozen’s study 8.3% of patients with PMR changed diagnosis, with more than half reclassified as RA. As a result, it is difficult to find rough methodological differences between these studies that could explain the different results obtained. The only variables remaining are the percentage mix of controls and the clinician’s ability to make a diagnosis and perform ultrasonography (US).

Which Additional Aids Could Be Useful to Identify and Support the Correct Diagnosis?

Ultrasonography. Is US the magic solution for this problem? In the original study, the addition of US increased specificity from 78% to 81%, but US decreased sensitivity from 68% to 66%. In another study, US highly increased specificity from 81.5% to 91.3%, and did not change sensitivity. Conversely, observed a decrease in sensitivity from 85.2% to 81.5%. Ozen, et al. found contrasting results, with an increase in sensitivity from 89.5% to 91.3% and a decrease in specificity from 57.7% to 52%. As reported, indicated best when used to differentiate PMR from noninflammatory shoulder disorders. US may increase our ability to classify PMR, but is probably not necessary for diagnosis because its effect on sensitivity is minimal or nonexistent. Other advanced imaging techniques, such as contrast-enhanced magnetic resonance imaging and positron emission tomography/computerized tomography, possibly share the same problem.

Inflammatory markers. The ACR/EULAR criteria require the presence of abnormal ESR and/or CRP, considered as a dichotomous variable. In their cohort, Ozen, et al. found that in establishing an ESR cutoff 2 times higher than the upper normal value, the best performance of sensitivity and specificity was achieved. When a CRP increase of at least 2 times was also set, specificity improved, but sensitivity slightly decreased. The reason why the authors of the ACR/EULAR criteria did not include CRP concentrations or ESR values in their set of criteria was that blood tests were not centralized or standardized. This was also the case for Ozen, et al.’s work and therefore their results, although theoretically sound, should be considered with caution. In the majority of elderly patients, however, mild degrees of systemic inflammation, often due to atherosclerosis, should be taken into account. This situation could also justify why, in the cohort of Ozen, et al., most patients with noninflammatory conditions of the shoulders had elevated ESR (79%) or CRP (57%). What is more, several reports have shown that up to 10% to 20% of PMR patients present with normal inflammatory indices. As a result, if only those patients with an increase of ESR or CRP are included in the PMR category, the correct diagnosis could be missed in about 1 in 5. What is needed is another prospective study where laboratory examinations are centralized.

Response to glucocorticoids. For many years a good response to glucocorticoid (GC) therapy has been used as a confirmatory criterion, an approach that could be misleading, because other diseases, whether rheumatic or not, are improved by GC. It is not clear how to define this good response. The ACR/EULAR study reported it as over 75% global response to 15 to 20 mg/day of prednisone. This result was not reached in 29% of patients at 4 weeks, which is contrary to the common opinion that patients with PMR always respond dramatically to GC. There was no association.
between the scores obtained on either algorithm and the response to GC at 4 and 26 weeks, which suggests that GC response cannot be used as part of PMR classification.

Workup of patients. Another potential pitfall is the subjectivity of each physician in deciding on the diagnostic investigations for patients with suspected PMR. Standardization of diagnostic procedures was another aim of the ACR/EULAR criteria group, which involved a wide range of participants, including patients and physicians (rheumatologists, internists, and general practitioners) to emphasize different viewpoints. The 2015 recommendations for management of PMR\(^\text{15}\) provide a list of mandatory laboratory tests, which should be performed at baseline for all patients. These include CRP and/or ESR, rheumatoid factor and/or anticyclic citrullinated peptide antibodies, blood cell count, glucose, creatinine concentration, liver function tests, bone profile, and dipstick urinalysis. In addition, in selected instances, additional tests such as protein electrophoresis, thyroid stimulating hormone, creatine kinase, Vitamin D, antinuclear antibodies, anti-neutrophil cytoplasmic antibodies, or tuberculin skin tests should be performed. Adoption of these procedures should diminish diagnostic variability among clinicians.

The ACR/EULAR criteria seem to constitute progress in the classification of PMR, although more data are needed on their prospective evaluation in different settings, with an eye to standardizing the numerous variables at work.

DARIO CAMELLINO, \textmd{MD}.
MARCO A. CIMMINO, \textmd{MD}.
Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Address correspondence to Dr. D. Camellino, Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 6, 16132 Genoa, Italy. E-mail: dario.camel@gmail.com

REFERENCES